The U.S. Supreme Court’s decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., 608 U.S. ___ (2026), is not simply another skinny-label case. For patent litigators, its larger significance is evidentiary. The decision forces a sharper distinction between three concepts that often blur together in induced-infringement cases: knowledge of infringement, commercial benefit from infringement, and affirmative conduct that encourages infringement. Only the third proves i